<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020566</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068608</org_study_id>
    <secondary_id>EURO-EWING-INTERGROUP-EE99</secondary_id>
    <secondary_id>EBMT-INTERGROUP-EE99</secondary_id>
    <secondary_id>EORTC-62981</secondary_id>
    <secondary_id>GPOH-AUSTRIA-INTERGROUP-EE99</secondary_id>
    <secondary_id>GPOH-GERMANY-INTERGROUP-EE99</secondary_id>
    <secondary_id>SFOP-INTERGROUP-EE99</secondary_id>
    <secondary_id>SWS-SAKK-INTERGROUP-EE99</secondary_id>
    <secondary_id>CCLG-INTERGROUP-EE99</secondary_id>
    <secondary_id>COG-AEWS0331</secondary_id>
    <secondary_id>EU-20213</secondary_id>
    <nct_id>NCT00020566</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma</brief_title>
  <official_title>European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Societe Francaise Oncologie Pediatrique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EBMT Solid Tumors Working Party</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Peripheral stem cell transplantation may allow the doctor to give higher doses of
      chemotherapy and kill more tumor cells. It is not yet known if combination chemotherapy is
      more effective with or without radiation therapy and/or surgery in treating Ewing's sarcoma.

      PURPOSE: This randomized phase III trial is studying different combination chemotherapy
      regimens to see how well they work when given with or without peripheral stem cell
      transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the event-free and overall survival of patients with tumor of the Ewing's family
           treated with standard induction chemotherapy comprising vincristine, dactinomycin,
           ifosfamide and etoposide (VIDE) followed by consolidation chemotherapy comprising
           vincristine, dactinomycin, and ifosfamide versus high-dose busulfan and melphalan
           (Bu-Mel) followed by autologous peripheral blood stem cell (PBSC) transplantation with
           or without radiotherapy and/or surgery.

      Secondary

        -  Determine the prognostic significance of EWS-Flil transcript in these patients.

        -  Determine the frequency and prognostic value of minimal disease in bone marrow and PBSC,
           as determined by the presence or absence of EWS-Flil transcript, in these patients.

        -  Determine the feasibility and toxicity of VIDE induction chemotherapy in these patients.

        -  Determine the response of these patients to VIDE induction chemotherapy.

        -  Determine the feasibility and toxicity of VAI consolodation chemotherapy in these
           patients.

        -  Determine the feasibility and toxicity of Bu-Mel consolodation chemotherapy in these
           patients.

        -  Determine event-free survival and overall survival of patients treated with these
           regimens by prognostic group analysis.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age
      and local treatment of the primary tumor (yes vs no).

      Patients receive induction chemotherapy comprising vincristine IV on day 1 and ifosfamide IV
      over 3 hours, doxorubicin IV over 4 hours, and etoposide IV over 1 hour on days 1-3 (VIDE).
      Treatment repeats every 21 days for 4 courses in the absence of unacceptable toxicity.
      Peripheral blood stem cells (PBSC) are collected after course 3 and/or 4. Patients are
      evaluated after course 4. Patients in need of early radiotherapy due to an axial tumor or
      patients who require radiotherapy to the brain and/or spinal cord (at any time during study)
      are assigned to group 1. Patients not needing early radiotherapy are assigned to group 2.

        -  Group 1: Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5
           and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent
           radiotherapy 5 days a week. Some patients may then undergo surgical resection of the
           tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and
           ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8
           courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord
           also undergo concurrent radiotherapy.

        -  Group 2: Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5
           and 6). Some patients may then undergo surgical resection of the tumor. All patients
           receive VAI chemotherapy as in group 1 for 1 course. Patients are randomized to 1 of 2
           consolidation therapy arms.

             -  Arm I: Patients receive 7 additional courses of VAI chemotherapy (courses 8-14).
                Patients with unresectable, partially resected, or inadequately resected disease
                undergo concurrent whole-lung radiotherapy for 6-12 days.

             -  Arm II: Patients receive high-dose chemotherapy comprising oral busulfan every 6
                hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive
                autologous PBSC IV on day 0. Patients with unresectable, partially resected, or
                inadequately resected disease undergo concurrent radiotherapy 5 days a week for at
                least 5 weeks.

      Patients are followed every 3 months for 4 years, every 6 months for 1 year, and then
      periodically thereafter.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK

      PROJECTED ACCRUAL: Approximately 1,200 patients will be accrued for this study within
      approximately 7 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2001</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility, toxicity, and response at 1 month following induction therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility and toxicity of consolidation regimens at 1 month following consolidation therapy</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dactinomycin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2, arm I</arm_group_label>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given orally and IV</description>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2, arm I</arm_group_label>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2, arm I</arm_group_label>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2, arm I</arm_group_label>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given orally and IV</description>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2, arm I</arm_group_label>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Given to patients deemed to require it</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2, arm I</arm_group_label>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Given to patients deemed to require it</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2, arm I</arm_group_label>
    <arm_group_label>Group 2, arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed tumor of the Ewing's family of bone or soft tissue

               -  Ewing's sarcoma

               -  Peripheral primitive neuroectodermal tumor

          -  Disease meeting one of the following criteria:

               -  Resectable localized disease (tumor volume less than 200 mL)

               -  Localized disease previously resected at diagnosis

               -  Unresectable disease (at least 200 mL tumor volume) but radiotherapy as local
                  control can be delayed

               -  Localized disease with early radiotherapy required

               -  Pulmonary and/or pleural metastases only

               -  Extrapulmonary/pleural metastases (skeleton, bone marrow, lymph nodes)

          -  No more than 45 days since definitive biopsy

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 50

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Renal function normal

          -  Glomerular filtration rate at least 60 mL/min

        Cardiovascular:

          -  Normal cardiac function

          -  Fractional shortening at least 29%

          -  Ejection fraction at least 40%

        Other:

          -  No medical, psychiatric, or social condition that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan W. Craft, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian J. Lewis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leeds Cancer Centre at St. James's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Odile Oberlin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian R. Judson, MA, MD, FRCP</last_name>
    <affiliation>Institute of Cancer Research, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heribert F. Juergens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helmut Gadner, MD, FRCPG</last_name>
    <role>Study Chair</role>
    <affiliation>St. Anna Kinderkrebsforschung</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Ulrich Exner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Balgrist Universitaetsklinik</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Ladenstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Anna Kinderkrebsforschung</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Hawkins, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - UAB Comprehensive Cancer Center</last_name>
      <phone>205-934-0309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016-7710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Boklan</last_name>
      <phone>602-546-0920</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkansas Cancer Research Center at University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Office - Arkansas Cancer Research Center at Uni</last_name>
      <phone>501-686-8274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - City of Hope Comprehensive Cancer Cen</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Mascarenhas</last_name>
      <phone>323-361-2529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert M. Cooper</last_name>
      <phone>323-783-5307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>95798</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neyssa M. Marina</last_name>
      <phone>650-723-5535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Oakland</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent A. Kiley</last_name>
      <phone>916-474-2326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Rady Children's Hospital - San Diego</last_name>
      <phone>858-966-5934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - UCSF Helen Diller Family Comprehensi</last_name>
      <phone>877-827-3222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado Center for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly W. Maloney</last_name>
      <phone>720-777-6673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Alfred I. duPont Hospital for Childre</last_name>
      <phone>302-651-5755</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's National Medical Center</last_name>
      <phone>202-884-2549</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric S. Sandler</last_name>
      <phone>904-697-3793</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Miami Sylvester Comprehensive Cancer Center Clin</last_name>
      <phone>866-574-5124</phone>
      <email>Sylvester@emergingmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramamoorthy Nagasubramanian</last_name>
      <phone>407-650-7230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey H. Schwartz</last_name>
      <phone>850-505-4790</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory A. Hale</last_name>
      <phone>727-767-4176</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Cancer Institute at St. Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - St. Joseph's Cancer Institute</last_name>
      <phone>800-882-4123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaplan Cancer Center at St. Mary's Medical Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narayana Gowda</last_name>
      <phone>561-844-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd M. Cooper</last_name>
      <phone>404-785-1838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cancer Research Center of Hawaii</last_name>
      <phone>808-586-2979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute at St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712-6297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenia Chang</last_name>
      <phone>208-381-2731</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of Chicago Cancer Research</last_name>
      <phone>773-834-7424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro A. De Alarcon</last_name>
      <phone>309-655-4242</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simmons Cooper Cancer Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794-9677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Simmons Cooper Cancer Institute</last_name>
      <phone>217-545-7929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Service</last_name>
      <phone>800-237-1225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Kosair Children's Hospital</last_name>
      <phone>502-629-5500</phone>
      <email>CancerResource@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's Hospital of New Orleans</last_name>
      <phone>504-894-5377</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alvin and Lois Lapidus Cancer Institute at Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M. Wiley</last_name>
      <phone>410-601-6266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>2115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Rodriguez-Galindo</last_name>
      <phone>617-632-4580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Hurley Medical Center</last_name>
      <phone>810-762-8057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Helen DeVos Children's Hospital</last_name>
      <phone>616-391-3050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Van Elslander Cancer Center at St. John Hospital and Medical Center</name>
      <address>
        <city>Grosse Pointe Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clincial Trials Office - Van Elslander Cancer Center at St. Jo</last_name>
      <phone>313-343-3166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-5381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey S. Lobel</last_name>
      <phone>269-341-6350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Breslin Cancer Center at Ingham Regional Medical Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Breslin Cancer Center at Ingham Regio</last_name>
      <phone>517-334-2765</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCOP - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805-1983</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>218-786-8364</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's Hospitals and Clinics of M</last_name>
      <phone>612-813-5193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Masonic Cancer Center at University o</last_name>
      <phone>612-624-2620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - All Mayo Clinic Locations</last_name>
      <phone>507-538-7623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - St. Paul</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102-2392</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>612-220-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Cancer Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail C. Megason</last_name>
      <phone>601-984-5220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxine L. Hetherington</last_name>
      <phone>816-234-3265</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Hayashi</last_name>
      <phone>314-454-2041</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109-2306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Bernstein</last_name>
      <phone>702-732-1493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Hackensack University Medical Center</last_name>
      <phone>201-996-2879</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Albert Einstein Cancer Center at Albe</last_name>
      <phone>718-904-2730</phone>
      <email>aecc@aecom.yu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Roswell Park Cancer Institute</last_name>
      <phone>877-275-7724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Herbert Irving Comprehensive Cancer C</last_name>
      <phone>212-305-8615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa R. Hackney</last_name>
      <phone>585-275-2981</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - SUNY Upstate Medical University Hospi</last_name>
      <phone>315-464-5476</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Blumenthal Cancer Center at Carolinas</last_name>
      <phone>704-355-2884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presbyterian Cancer Center at Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233-3549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Presbyterian Cancer Center at Presbyt</last_name>
      <phone>704-384-5369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Duke Cancer Institute</last_name>
      <phone>888-275-3853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Center at ECU Medical School</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Leo W. Jenkins Cancer Center at ECU M</last_name>
      <phone>252-744-2391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cincinnati Children's Hospital Medica</last_name>
      <phone>513-636-2799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousif (Joe) H. Matloub</last_name>
      <phone>216-844-3345</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente</last_name>
      <phone>866-223-8100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura T. Martin</last_name>
      <phone>614-722-3582</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Children's - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404-1815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmett H. Broxson</last_name>
      <phone>937-641-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Toledo Hospital</last_name>
      <phone>419-824-1842</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tod Children's Hospital</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Tod Children's Hospital</last_name>
      <phone>330-884-3955</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Y. McNall-Knapp</last_name>
      <phone>405-271-5311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Legacy Emanuel Children's Hospital</last_name>
      <phone>503-413-2560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip M. Monteleone</last_name>
      <phone>484-884-3333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John F. Kuttesch</last_name>
      <phone>717-531-6012</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Fox</last_name>
      <phone>267-425-3010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's Hospital of Pittsburgh</last_name>
      <phone>412-692-7056</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Greenville Hospital Cancer Center</last_name>
      <phone>864-241-6251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>605-322-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Tennessee Children's Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray C. Pais</last_name>
      <phone>865-541-8266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center School of Medicine - Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osvaldo Regueira</last_name>
      <phone>806-354-5434x282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Driscoll Children's Hospital</last_name>
      <phone>361-694-5311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Simmons Comprehensive Cancer Center a</last_name>
      <phone>866-460-4673; 214-648-7097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cook's Children's Medical Center</last_name>
      <phone>682-885-2103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie R. Langevin</last_name>
      <phone>210-567-7477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3993</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Estrada</last_name>
      <phone>210-575-7268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113-1100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip E. Barnette</last_name>
      <phone>801-662-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly P. Dunsmore</last_name>
      <phone>434-924-5105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Inova Fairfax Hospital</last_name>
      <phone>703-208-6650</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507-1971</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric J. Lowe</last_name>
      <phone>757-668-7243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie R. Park</last_name>
      <phone>206-987-2106</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center at Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99220-2555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy L. Felgenhauer</last_name>
      <phone>509-474-2777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's Hospital and Health Center - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert G. Irwin</last_name>
      <phone>253-403-3481</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University Health Sciences Center - Charleston</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen R. Chauvenet</last_name>
      <phone>304-388-1552</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital Regional Cancer Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - St. Vincent Hospital Regional Cancer</last_name>
      <phone>920-433-8889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Marshfield Clinic - Marshfield Center</last_name>
      <phone>800-782-1581 ext. 94457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center at Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael E. Kelly</last_name>
      <phone>414-456-4170</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey B. McCowage</last_name>
      <phone>61298452122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Irving</last_name>
      <phone>617-3636-8671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria L. Kirby</last_name>
      <phone>61881617411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine H. Cole</last_name>
      <phone>011-6189340-8238</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Jayantilal` S. Desai</last_name>
      <phone>780-248-5530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's and Women's Hospital of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caron Strahlendorf</last_name>
      <phone>604-875-3576</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochelle A. Yanofsky</last_name>
      <phone>204-787-4163</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Janeway Children's Health and Rehabilitation Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Anne B. Goodyear</last_name>
      <phone>709-777-4303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3J 3G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret C. Yhap</last_name>
      <phone>902-470-8778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Baruchel</last_name>
      <phone>416-813-7795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvan Samson</last_name>
      <phone>514-345-4931x2790</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre at the University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Mpofu</last_name>
      <phone>306-655-2744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Michon</last_name>
      <phone>418-656-4141X47191</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Starship Children's Health</name>
      <address>
        <city>Auckland</city>
        <zip>1</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lochie R. Teague</last_name>
      <phone>649-307-4949x22423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Jorge Children's Hospital</name>
      <address>
        <city>Santurce</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis A. Clavell</last_name>
      <phone>787-728-1575</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <results_reference>
    <citation>Ladenstein R, Ptschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jrgens H. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010 Jul 10;28(20):3284-91. doi: 10.1200/JCO.2009.22.9864. Epub 2010 Jun 14.</citation>
    <PMID>20547982</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslbck M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jrgens H, Kovar H. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol. 2010 Apr 20;28(12):1982-8. doi: 10.1200/JCO.2009.23.3585. Epub 2010 Mar 22.</citation>
    <PMID>20308673</PMID>
  </results_reference>
  <results_reference>
    <citation>Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, Michon J, Zoubek A, Juergens H, Craft A. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006 Jul;47(1):22-9.</citation>
    <PMID>16572419</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <keyword>localized Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Dactinomycin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

